ERBB2 and breast cancer: In postmenopausal women, the diagnosis of HR−/HER2+ breast cancer was more likely in 2017 (OR = 2.24, 95% CI 1.08, 4.63, p = 0.03) and 2018 (OR = 2.91, 95% CI 1.45, 5.85, p = 0.003) compared to 2015 (Table 3).